Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521

Watchlist Manager
Zhejiang Huahai Pharmaceutical Co Ltd Logo
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Watchlist
Price: 18.7 CNY -0.58%
Market Cap: 27.4B CNY
Have any thoughts about
Zhejiang Huahai Pharmaceutical Co Ltd?
Write Note

Zhejiang Huahai Pharmaceutical Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhejiang Huahai Pharmaceutical Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Pre-Tax Income
ÂĄ1.5B
CAGR 3-Years
18%
CAGR 5-Years
25%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ5.9B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
-ÂĄ769m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Huahai Pharmaceutical Co Ltd
Glance View

Market Cap
27.4B CNY
Industry
Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co., Ltd., nestled in the vibrant economic landscape of China, has crafted a reputation as a pioneering force in the pharmaceutical industry. The company began its journey with a modest ambition: to establish itself as a reliable provider of Active Pharmaceutical Ingredients (APIs). Over the years, Huahai has broadened its horizons beyond APIs, expanding into the realm of finished dosage forms. This strategic diversification has enabled the company to control the entire value chain—from manufacturing raw pharmaceutical compounds to delivering final medicines ready for consumption. This integrated approach not only enhances quality control but also fortifies their market presence globally, allowing Huahai to cement its status as a formidable player in pharmaceutical exports. What sets Zhejiang Huahai apart is its steadfast commitment to innovation and compliance with international standards. The company channels considerable resources into research and development, focusing on therapeutic areas such as cardiovascular and central nervous system disorders. This devotion to R&D not only fuels the pipeline of new products but also enhances profitability by ensuring a steady stream of high-demand medications. Furthermore, Huahai's strategic partnerships with global pharmaceutical giants shape a dual-edged strategy of market expansion and shared expertise. By working closely with partners worldwide, Huahai ensures that its products remain at the cutting edge of medical advancements while maintaining regulatory compliance in diverse markets. This approach is what powers Huahai's steady revenue growth and robust competitive edge in the ever-evolving pharmaceutical sector.

Intrinsic Value
27.11 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Zhejiang Huahai Pharmaceutical Co Ltd's Pre-Tax Income?
Pre-Tax Income
1.5B CNY

Based on the financial report for Sep 30, 2024, Zhejiang Huahai Pharmaceutical Co Ltd's Pre-Tax Income amounts to 1.5B CNY.

What is Zhejiang Huahai Pharmaceutical Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
17%

Over the last year, the Pre-Tax Income growth was 8%. The average annual Pre-Tax Income growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been 18% over the past three years , 25% over the past five years , and 17% over the past ten years .

Back to Top